Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials

被引：121

作者：

Robinson, Jennifer G. ^{[1
]}

Wang, Songfeng ^{[2
]}

Jacobson, Terry A. ^{[3
]}

机构：

[1] Univ Iowa, Iowa City, IA 52242 USA

[2] Univ S Carolina, Columbia, SC 29208 USA

[3] Emory Univ, Atlanta, GA 30322 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2012年 / 110卷 / 10期

关键词：

CORONARY-HEART-DISEASE; HIGH-DOSE ATORVASTATIN; NON-HDL CHOLESTEROL; LDL-CHOLESTEROL; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; TREATED PATIENTS; SURGICAL CONTROL; ARTERY-DISEASE; STATIN THERAPY;

D O I：

10.1016/j.amjcard.2012.07.007

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

This study evaluated the relation between apolipoprotein B (apoB) decrease and coronary heart disease, stroke, and cardiovascular disease risk. Bayesian random-effects meta-analysis was used to evaluate the association of mean absolute apoB decrease (milligrams per deciliter) with relative risk of coronary heart disease (nonfatal myocardial infarction and coronary heart disease death), stroke (nonfatal stroke and fatal stroke), or cardiovascular disease (coronary heart disease, stroke, and coronary revascularization). Analysis included 25 trials (n = 131,134): 12 on statin, 4 on fibrate, 5 on niacin, 2 on simvastatin ezetimibe, 1 on ileal bypass surgery, and 1 on aggressive versus standard low-density lipoprotein (LDL) cholesterol and blood pressure targets. Combining the 25 trials, each 10-mg/dl decrease in apoB was associated with a 9% decrease in coronary heart disease, no decrease in stroke, and a 6% decrease in major cardiovascular disease risk. Non-high-density lipoprotein (non-HDL) cholesterol decrease modestly outperformed apoB decrease for prediction of coronary heart disease (Bayes factor [BF] 1.45) and cardiovascular disease (BF 2.07) risk decrease; apoB decrease added to non-HDL cholesterol plus LDL cholesterol decrease slightly improved cardiovascular disease risk prediction (1.13) but did not improve coronary heart disease risk prediction (BF 1.03) and worsened stroke risk prediction (BF 0.83). In the 12 statin trials, apoB and non-HDL cholesterol decreases similarly predicted cardiovascular disease risk; apoB improved coronary heart disease prediction when added to non-HDL cholesterol/LDL cholesterol decrease (BF 3.33) but did not improve stroke risk prediction when added to non-HDL cholesterol/LDL cholesterol decrease (BF 1.06). In conclusion, across all drug classes, apoB decreases did not consistently improve risk prediction over LDL cholesterol and non-HDL cholesterol decreases. For statins, apoB decreases added information to LDL cholesterol and non-HDL cholesterol decreases for predicting coronary heart disease but not stroke or overall cardiovascular disease risk decrease. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;110:1468-1476)

引用

页码：1468 / 1476

页数：9

共 57 条

[1]

The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial [J].

Alaupovic, P ;

Fesmire, JD ;

Hunnighake, D ;

Domanski, M ;

Forman, S ;

Knatterud, GL ;

Forrester, J ;

Herd, JA ;

Hoogwerf, B ;

Campeau, L ;

Gobel, FL .

ATHEROSCLEROSIS, 1999, 146 (02) :369-379

[2]

Amarenco P, 2006, NEW ENGL J MED, V355, P549

[3]

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial [J].

Armitage, Jane ;

Bowman, Louise ;

Wallendszus, Karl ;

Bulbulia, Richard ;

Rahimi, Kazem ;

Haynes, Richard ;

Parish, Sarah ;

Peto, Richard ;

Collins, Rory ;

Meade, T. ;

Sleight, P. ;

Collins, R. ;

Armitage, J. ;

Bowman, L. ;

Parish, S. ;

Peto, R. ;

Barton, J. ;

Bray, C. ;

Wincott, E. ;

Dayanandan, R. ;

Clarke, R. ;

Graham, I. ;

Simpson, D. ;

Warlow, C. ;

Wilken, D. ;

Tobert, J. ;

Mushner, T. ;

Doll, R. ;

Wilhelmsen, L. ;

Fox, K. ;

Hill, C. ;

Sandercock, P. ;

Webster, J. ;

Henderson, J. ;

Nixon, A. ;

Lackie, S. ;

Thompson, J. ;

Brown, M. ;

Blackwood, S. ;

Morgan, M. ;

Rhoden, W. ;

Saeed, B. ;

Houghton, M. ;

Nicholson, A. ;

Simpson, C. ;

Hoburn, B. ;

Cooper, I. ;

Gallivan, A. ;

Pickerell, E. ;

Hancock, J. .

LANCET, 2010, 376 (9753) :1658-1669

[4]

Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease [J].

Baigent, C. ;

Landray, M. ;

Reith, C. ;

Dasgupta, T. ;

Emberson, J. ;

Herrington, W. ;

Lewis, D. ;

Mafham, M. ;

Collins, R. ;

Baigent, C. ;

Landray, M. ;

Bray, C. ;

Chen, Y. ;

Baxter, A. ;

Young, A. ;

Hill, M. ;

Knott, C. ;

Cass, A. ;

Feldt-Rasmussen, B. ;

Fellstroem, B. ;

Grobbee, R. ;

Groenhagen-Riska, C. ;

Haas, M. ;

Holdaas, H. ;

Hooi, L. S. ;

Jiang, L. ;

Kasiske, B. ;

Krairittichai, U. ;

Levin, A. ;

Massy, Z. ;

Tesar, V. ;

Walker, R. ;

Wanner, C. ;

Wheeler, D. ;

Wiecek, A. ;

Dasgupta, T. ;

Lewis, D. ;

Mafham, M. ;

Majoni, W. ;

Reith, C. ;

Simpson, D. ;

Strony, J. ;

Musliner, T. ;

Agodoa, L. ;

Armitage, J. ;

Chen, Z. ;

Craig, J. ;

de Zeeuw, D. ;

Gaziano, M. .

AMERICAN HEART JOURNAL, 2010, 160 (05) :785-U28

[5]

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].

Baigent, C. ;

Blackwell, L. ;

Emberson, J. ;

Holland, L. E. ;

Reith, C. ;

Bhala, N. ;

Peto, R. ;

Barnes, E. H. ;

Keech, A. ;

Simes, J. ;

Collins, R. .

LANCET, 2010, 376 (9753) :1670-1681

[6]

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].

Baigent, C ;

Keech, A ;

Kearney, PM ;

Blackwell, L ;

Buck, G ;

Pollicino, C ;

Kirby, A ;

Sourjina, T ;

Peto, R ;

Collins, R ;

Simes, J .

LANCET, 2005, 366 (9493) :1267-1278

[7]

Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis [J].

Boekholdt, S. Matthijs ;

Arsenault, Benoit J. ;

Mora, Samia ;

Pedersen, Terje R. ;

LaRosa, John C. ;

Nestel, Paul J. ;

Simes, R. John ;

Durrington, Paul ;

Hitman, Graham A. ;

Welch, K. M. A. ;

DeMicco, David A. ;

Zwinderman, Aeilko H. ;

Clearfield, Michael B. ;

Downs, John R. ;

Tonkin, Andrew M. ;

Colhoun, Helen M. ;

Gotto, Antonio M., Jr. ;

Ridker, Paul M. ;

Kastelein, John J. P. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (12) :1302-1309

[8]

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease [J].

Brown, BG ;

Zhao, XQ ;

Chait, A ;

Fisher, LD ;

Cheung, MC ;

Morse, JS ;

Dowdy, AA ;

Marino, EK ;

Bolson, EL ;

Alaupovic, P ;

Frohlich, J ;

Albers, JJ ;

Serafini, L ;

Huss-Frechette, E ;

Wang, S ;

DeAngelis, D ;

Dodek, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (22) :1583-1592

[9]

REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B [J].

BROWN, G ;

ALBERS, JJ ;

FISHER, LD ;

SCHAEFER, SM ;

LIN, JT ;

KAPLAN, C ;

ZHAO, XQ ;

BISSON, BD ;

FITZPATRICK, VF ;

DODGE, HT .

NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) :1289-1298

[10]

EFFECT OF PARTIAL ILEAL BYPASS-SURGERY ON MORTALITY AND MORBIDITY FROM CORONARY HEART-DISEASE IN PATIENTS WITH HYPERCHOLESTEROLEMIA - REPORT OF THE PROGRAM ON THE SURGICAL CONTROL OF THE HYPERLIPIDEMIAS (POSCH) [J].

BUCHWALD, H ;

VARCO, RL ;

MATTS, JP ;

LONG, JM ;

FITCH, LL ;

CAMPBELL, GS ;

PEARCE, MB ;

YELLIN, AE ;

EDMISTON, WA ;

SMINK, RD ;

SAWIN, HS ;

CAMPOS, CT ;

HANSEN, BJ ;

TUNA, N ;

KARNEGIS, JN ;

SANMARCO, ME ;

AMPLATZ, K ;

CASTANEDAZUNIGA, WR ;

HUNTER, DW ;

BISSETT, JK ;

WEBER, FJ ;

STEVENSON, JW ;

LEON, AS ;

CHALMERS, TC .

NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (14) :946-955

← 1 2 3 4 5 6 →